Pharmaceutical - Licensing

Filter

Current filters:

Licensing

Popular Filters

1 to 25 of 753 results

Ranbaxy to distribute Cipher’s isotretinoin product in Brazil

25-07-2014

Canada’s Cipher Pharmaceuticals has signed a definitive distribution and supply agreement with India’s…

BrazilCipher PharmaceuticalsDermatologicalsIsotretinoinLicensingPharmaceuticalRanbaxy Laboratories

Bristol-Myers and Ono Pharma enter Asia oncology accord

Bristol-Myers and Ono Pharma enter Asia oncology accord

24-07-2014

US pharma major Bristol-Myers Squibb and Japan’s Ono Pharmaceutical have signed a strategic collaboration…

Asia-PacificBristol-Myers SquibbJapanLicensinglirilumabMelanomaOncologyOno PharmaceuticalOpdivoPharmaceuticalurelumabYervoy

LEO Pharma strikes global dermatology deal with KLOK Tech

LEO Pharma strikes global dermatology deal with KLOK Tech

16-07-2014

Danish dermatology specialist LEO Pharma and Canada’s KLOX Technologies, both privately-held companies,…

Acne vulgarisDermatologicalsGlobalKLOX TechnologiesLEO PharmaLicensingPharmaceutical

moksha8 to commercialize BIAL’s eslicarbazepine in Brazil and Mexico

moksha8 to commercialize BIAL’s eslicarbazepine in Brazil and Mexico

15-07-2014

Portuguese drugmaker BIAL and Brazil-based moksha8 have entered an exclusive license for the commercialization…

BIALBrazileslicarbazepineExaliefLicensingMexicoMoksha8NeurologicalPharmaceuticalPortugalZebinix

Codexis leaps on licensing deal with GlaxoSmithKline

Codexis leaps on licensing deal with GlaxoSmithKline

15-07-2014

Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries, saw its share…

CodeEvolverCodeEvolver protein engineering platform technologyCodexisGlaxoSmithKlineLicensingPharmaceuticalProductionUK

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

10-07-2014

USA-based Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Japanese…

andexanet alfaCardio-vascularDaiichi SankyoedoxabanJapanLicensingPharmaceuticalPortola PharmaceuticalsResearchSavaysaUSA

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

08-07-2014

Chinese drugmaker Yabao Pharmaceutical has entered a strategic partnership with US pharma major Eli Lilly…

ChinaDiabetesEli LillyLicensingPharmaceuticalYabao Pharmaceutical

UCB and Dermira link up for Cimzia in dermatology

UCB and Dermira link up for Cimzia in dermatology

03-07-2014

Belgium’s largest drugmaker UCB and Dermira, a privately held USA-based dermatology company, have entered…

CanadaCimziaDermatologicalsDermiraEuropeLicensingPharmaceuticalResearchUCBUSA

Jazz Pharma gains Americas rights to defibrotide from Sigma-Tau

Jazz Pharma gains Americas rights to defibrotide from Sigma-Tau

02-07-2014

Ireland-headquartered drugmaker Jazz Pharmaceuticals has signed a definitive agreement Pharmaceuticals…

defibrotideGentiumJazz PharmaceuticalsLicensingNephrology and HepatologyNorth AmericaPharmaceuticalSigma-TauSouth America

CureVac in deal with Sanofi Pasteur for mRNA-based prophylactic vaccine

01-07-2014

German clinical-stage biopharma company CureVac has entered into an exclusive license agreement with…

LicensingPharmaceuticalSanofiSanofi PasteurVaccines

Boston Strategics in-licenses Eisai’s cancer candidate E6201

01-07-2014

US clinical-stage drug R&D company Boston Strategics Corp has entered into an exclusive licensing and…

Boston Strategics CorpE6201EisaiLicensingOncologyPharmaceutical

Helsinn out-licenses potential NSCLC drug in Turkey

Helsinn out-licenses potential NSCLC drug in Turkey

30-06-2014

Privately-held Swiss pharma group Helsinn said today that rights to anamorelin, its innovative ghrelin…

GEN IlacHelsinnLicensingOncologyPharmaceuticalTurkey

Vectura signs additional deal with unnamed US pharma company

Vectura signs additional deal with unnamed US pharma company

30-06-2014

UK developer of inhaled therapies Vectura Group has signed a US collaboration, development and license…

LicensingPharmaceuticalRespiratory and PulmonaryUKUSAVecturaVR315

Teijin inks exclusive deal with Sigma-Tau for EZN-2279 in Japan

Teijin inks exclusive deal with Sigma-Tau for EZN-2279 in Japan

26-06-2014

Japanese firm Teijin has entered into an agreement with the UK subsidiary of privately-owned Italian…

EZN-2279ImmunologicalsJapanLicensingPharmaceuticalSigma-TauTeijin

BioAlliance Pharma signs deal with EMS for Sitavig in Brazil

BioAlliance Pharma signs deal with EMS for Sitavig in Brazil

26-06-2014

French oncology specialist BioAlliance Pharma SA has announced a license agreement for Sitavig (acyclovir…

Antibiotics and Infectious diseasesBioAlliance PharmaBrazilLicensingPharmaceuticalSitavig

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

24-06-2014

US drugmaker Ligand Pharmaceuticals has signed an exclusive global license accord with TG Therapeutics…

ImmunologicalsLicensingLigand PharmaceuticalsOncologyPharmaceuticalTG Therapeutics

Sanofi returns rights for cancer candidate MM-121 to Merrimack

Sanofi returns rights for cancer candidate MM-121 to Merrimack

20-06-2014

USA-based Merrimack Pharmaceuticals says it has reached an agreement with French drug major Sanofi to…

LicensingMerrimack PharmaceuticalsMM-121OncologyPharmaceuticalSanofi

Pfizer inks multi-million $ cancer immunology deal with Cellectis

Pfizer inks multi-million $ cancer immunology deal with Cellectis

18-06-2014

France-based genome engineering specialist Cellectis saw its shares rocket nearly 50% to 9.26 euros,…

CellectisLicensingMergers & AcquisitionsOncologyPfizerPharmaceutical

MRC Technology sells its melanocortin receptors program to Pfizer

MRC Technology sells its melanocortin receptors program to Pfizer

18-06-2014

UK-based technology transfer organization MRC Technology has sold its melanocortin receptors (MCRs) program,…

LicensingMRC TechnologyPfizerPharmaceutical

Merck pulls out of license deal with Ono Pharma for MS drug ceralifimod

Merck pulls out of license deal with Ono Pharma for MS drug ceralifimod

17-06-2014

German drug major Merck KGaA revealed this morning that, by mutual agreement, it has terminated its licensing…

ceralifimodLicensingMerck KGaAMerck SeronoNeurologicalOno PharmaceuticalPharmaceutical

1 to 25 of 753 results

Back to top